ERBB2 and neoplasm: 177Lu‐labelled trastuzumab administered to patients with HER2+ BC localised in primary and metastatic tumours showed high contrast on imaging by SPECT/CT, indicating its potential for the diagnosis of HER2‐positive BC [87, 88].